chenodeoxycholic acid has been researched along with pravastatin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kubo, M; Matsuzawa, Y; Miki, H; Nakamura, T; Takemura, K; Tarui, S | 1 |
| Fujiyama, J; Kuriyama, M; Osame, M; Tokimura, Y; Utatsu, Y | 1 |
| Fuchs, M; Hörmann, E; Scheibner, J; Stange, EF; Tauber, G | 1 |
| Fuchs, M; Hörmann, E; Scheibner, J; Schiemann, M; Stange, EF; Tauber, G | 1 |
| Clarenbach, JJ; Dotti, MT; Federico, A; Kelleher, JK; Lindenthal, B; von Bergmann, K | 1 |
| Cariou, B; Caron, S; Costet, P; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Staels, B | 1 |
| Fink, JC; Kane, MA; Karra, VK; Krug, SA; Metry, M; Polli, JE; Shu, Y; Wang, H | 1 |
1 review(s) available for chenodeoxycholic acid and pravastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for chenodeoxycholic acid and pravastatin
| Article | Year |
|---|---|
Differential effects of metformin-mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Chenodeoxycholic Acid; Humans; Metformin; Pravastatin | 2022 |
9 other study(ies) available for chenodeoxycholic acid and pravastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Topics: Adult; Anticholesteremic Agents; Bile Acids and Salts; Brain Diseases; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Muscular Diseases; Naphthalenes; Pravastatin; Tendons; Xanthomatosis | 1991 |
Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
Topics: Adult; Apolipoproteins; Brain Diseases; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Drug Therapy, Combination; Electrophysiology; Humans; Lipids; Lipoproteins; Male; Middle Aged; Muscular Diseases; Phytosterols; Pravastatin; Tendons; Xanthomatosis | 1994 |
Biliary cholesterol secretion and bile acid formation in the hamster: the role of newly synthesized cholesterol.
Topics: Animals; Bile; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholic Acids; Cricetinae; Female; Liver; Mesocricetus; Pravastatin | 1994 |
Bile acid synthesis from newly synthesized vs. preformed cholesterol precursor pools in the rat.
Topics: Acetates; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholic Acid; Cholic Acids; Circadian Rhythm; Enterohepatic Circulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Pravastatin; Protein Precursors; Rats; Rats, Wistar | 1993 |
Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
Topics: Adult; Bile; Bile Acids and Salts; Carbon Isotopes; Chenodeoxycholic Acid; Cholestanol; Cholestanols; Cholesterol; Female; Gas Chromatography-Mass Spectrometry; Humans; Isotope Labeling; Lanosterol; Male; Middle Aged; Pravastatin; Sterols; Xanthomatosis, Cerebrotendinous | 2005 |
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
Topics: Chenodeoxycholic Acid; DNA-Binding Proteins; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Pravastatin; Proprotein Convertase 9; Proprotein Convertases; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; RNA, Messenger; Serine Endopeptidases; Transcription Factors; Transcription, Genetic | 2008 |